nicotinamide/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on all-cause mortality
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“All-cause mortality was comparable between the treatment groups [NAMR: 5.9% (n = 32) versus placebo: 6.0% (n = 11), P = 1.00].”
Quoted verbatim from Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial.. - Study
- RCT
- Duration
- 12 months
- Dose
- modified-release nicotinamide 250-1500 mg/day (one to six 250 mg capsules once daily before bed)
- Population
- Safety population of adults on maintenance haemodialysis with hyperphosphataemia, modified-release nicotinamide versus placebo, both arms on their individual phosphate binders
Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial.2023PMID:35751625Industry fundedPermalink
Keep reading
- Everything the graph holds on nicotinamide
- Every compound studied against All-cause mortality
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PFZ3S5D0QE5EBFZAG9FC47